Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q1 2025 · 10-Q
Revenue$18.52M$18.52M+11.5% vs Q1 2024 Net Income-$11.26M-$11.26MN/M vs Q1 2024 EPS Diluted-$0.25-$0.25N/M vs Q1 2024 Gross Profit$12,512,000+10.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flow-$9,725,000N/M Free Cash Flowderived-$9,757,000N/M Margins · derivedGross margin67.6%−0.7 pt vs Q1 2024
Operating margin-56.5%−27.5 pt vs Q1 2024
Net margin-60.8%−26.7 pt vs Q1 2024
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end